Early Metabolic Profile in Neonates with Maternal Intrahepatic Cholestasis of Pregnancy

Bengisu Guner Yilmaz1, Saygin Abali2, Ariorad Moniri3

  • 1Division of Neonatology, Department of Pediatrics, School of Medicine, Acibadem Mehmet Ali Aydinlar University, Istanbul 34638, Turkey.

PubMed

Insights

Intrahepatic cholestasis of pregnancy (ICP) alters neonatal metabolism, affecting amino acids and fatty acid oxidation. This study highlights potential fetal adaptations to the intrauterine cholestatic environment.

Area of Science:

  • Neonatal Metabolism
  • Perinatal Medicine
  • Biochemistry

Background:

  • Intrahepatic cholestasis of pregnancy (ICP) is linked to adverse perinatal outcomes.
  • The specific metabolic effects of ICP on newborns are not well understood.
  • This study examines metabolic profiles in neonates born to mothers with ICP.

Purpose of the Study:

  • To investigate amino acid, carnitine, and acylcarnitine profiles in neonates born to mothers with ICP.
  • To characterize neonatal metabolic alterations associated with ICP.
  • To identify potential biomarkers for ICP-related neonatal complications.

Main Methods:

  • Retrospective analysis of 299 neonates born to mothers with ICP.
  • Comparison between ICP-term neonates (n=150) and term controls (n=150).
  • LC-MS/MS analysis of capillary blood samples for amino acid and acylcarnitine profiles.

Main Results:

  • Elevated levels of certain amino acids (e.g., alanine, leucine/isoleucine) and acylcarnitines observed in ICP-term neonates.
  • Decreased levels of other amino acids (e.g., argininosuccinic acid) and acylcarnitines noted in ICP-term neonates.
  • Ornithine and leucine/isoleucine showed strong discriminatory potential (AUC > 0.73).

Conclusions:

  • Neonatal metabolic profiles in ICP reveal disruptions in amino acid metabolism, fatty acid oxidation, and mitochondrial function.
  • These alterations suggest fetal adaptation to the intrauterine cholestatic environment.
  • Metabolomic profiling offers insights into maternal-fetal interactions and aids in risk stratification.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
171
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
165
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
225
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
679